NASDAQ:ALEC Alector Q3 2025 Earnings Report $2.35 -0.04 (-1.67%) As of 11:09 AM Eastern ProfileEarnings HistoryForecast Alector EPS ResultsActual EPS-$0.34Consensus EPS -$0.42Beat/MissBeat by +$0.08One Year Ago EPSN/AAlector Revenue ResultsActual Revenue$3.26 millionExpected Revenue$3.49 millionBeat/MissMissed by -$227.00 thousandYoY Revenue GrowthN/AAlector Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time4:00PM ETUpcoming EarningsAlector's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Alector Earnings HeadlinesAlector, Inc. (ALEC) Latest Press Releases & Corporate News - Yahoo FinanceAugust 26 at 10:47 PM | finance.yahoo.comBank of America Securities Sticks to Its Sell Rating for Alector (ALEC)August 13, 2026 | theglobeandmail.comTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Executive Order 14241 could trigger something even bigger. In a new documentary, Stansberry names five assets to watch before America's new dollar rolls out and explains why the U.S. government is buying stakes in small mining companies, a move not seen since World War II. He also points to a December gathering of world leaders at a Trump resort in Miami that could reveal the new dollar to the world.August 28 at 1:00 AM | Porter & Company (Ad)Alector, Inc. (ALEC) Stock Price, News, Quote & History - Yahoo FinanceAugust 12, 2026 | finance.yahoo.comAlector: Q2 Earnings SnapshotAugust 6, 2026 | sfgate.comAlector Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comSee More Alector Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email. Email Address About AlectorAlector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia. The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe. Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide. Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.View Alector ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes ShapeCrowdStrike’s “Mythos Moment” Tests the Bigger AI Security TradeIntuit’s Earnings Reset May Be More Pivot Than PlungeSalesforce Turns the Corner as AI Fears Start to FadeNVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout IsMarvell’s Big AI Test Comes One Day After NVIDIA’s Blowout Quarter3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
